|
1
|
Hao H, Zhou Z, Li S, Maquilan G, Folkert
MR, Iyengar P, Westover KD, Albuquerque K, Liu F, Choy H, et al:
Shell feature: A new radiomics descriptor for predicting distant
failure after radiotherapy in non-small cell lung cancer and cervix
cancer. Phys Med Biol. 63:0950072018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shaw AT and Engelman JA: Ceritinib in
ALK-rearranged non-small-cell lung cancer. N Engl J Med 3.
70:2537–2539. 2014.
|
|
3
|
Shroff GS, Viswanathan C, Carter BW,
Benveniste MF, Truong MT and Sabloff BS: Staging lung cancer:
Metastasis. Radiol Clin North Am. 56:411–418. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Legras A, Pécuchet N, Imbeaud S, Pallier
K, Didelot A, Roussel H, Gibault L, Fabre E, Le Pimpec-Barthes F,
Laurent-Puig P and Blons H: Epithelial-to-mesenchymal transition
and microRNAs in lung cancer. Cancers (Basel). 9. pp. E1012017,
View Article : Google Scholar
|
|
5
|
Pawlak K, Gabryel P, Kujawska A, Kasprzyk
M, Piwkowski C, Kuffel B and Dyszkiewicz W: Long-term results of
surgical treatment of non-small cell lung cancer in patients over
75 years of age. Kardiochir Torakochirurgia Pol. 15:65–71.
2018.PubMed/NCBI
|
|
6
|
Xu X, Chen D, Ye B, Zhong F and Chen G:
Curcumin induces the apoptosis of non-small cell lung cancer cells
through a calcium signaling pathway. Int J Mol Med. 35:1610–1616.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Monteleone I, Pallone F and Monteleone G:
Interleukin-23 and Th17 cells in the control of gut inflammation.
Mediators Inflamm. 2009.297645:2009.
|
|
8
|
Fu ZQ, Zhou Q, Zhu S and Liu W: Anti-tumor
mechanism of IL-21 used alone and in combination with
5-fluorouracil in vitro on human gastric cancer cells. J Biol Regul
Homeost Agents. 32:619–625. 2018.PubMed/NCBI
|
|
9
|
Chen C, Liu X and Ren Y: Interleukin 21
treatment in a murine model as a novel potential cytokine
immunotherapy for colon cancer. Adv Clin Exp Med. 27:583–589. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang Y, Wang J, Wu D, Li M, Zhao F, Ren
M, Cai Y and Dou J: IL-21-secreting hUCMSCs combined with miR-200c
inhibit tumor growth and metastasis via repression of Wnt/β-catenin
signaling and epithelial-mesenchymal transition in epithelial
ovarian cancer. Onco Targets Ther. 11:2037–2050. 2018. View Article : Google Scholar :
|
|
11
|
Liu L, Shi F, Li S, Liu X, Wei L, Zhang J,
Ju X and Yu J: IL-21 polymorphisms rs907715 and rs2221903 are
associated with decreased non-small cell lung cancer
susceptibility. Int J Clin Exp Med. 8:19460–19465. 2015.
|
|
12
|
Qiu L, Yu Q, Zhou Y, Zheng S, Tao J, Jiang
Q and Yuan G: Functionally impaired follicular helper T cells
induce regulatory B cells and CD14+ human leukocyte
antigen-DR- cell differentiation in non-small cell lung
cancer. Cancer Sci. 109:3751–3761. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kaltenmeier C, Gawanbacht A, Beyer T,
Lindner S, Trzaska T, van der Merwe JA, Härter G, Grüner B,
Fabricius D, Lotfi R, et al: CD4+ T cell-derived IL-21
and deprivation of CD40 signaling favor the in vivo development of
granzyme B-expressing regulatory B cells in HIV patients. J
Immunol. 194:3768–3777. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang JY, Wang X, Wang XJ, Zheng BZ, Wang
Y, Wang X and Liang B: Curcumin inhibits the growth via
Wnt/β-catenin pathway in non-small-cell lung cancer cells. Eur Rev
Med Pharmacol Sci. 22:7492–7499. 2018.PubMed/NCBI
|
|
15
|
Wang XH, Cui YX, Wang ZM and Liu J:
Down-regulation of FOXR2 inhibits non-small cell lung cancer cell
proliferation and invasion through the Wnt/β-catenin signaling
pathway. Biochem Biophys Res Commun. 500:229–235. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Spranger S, Bao R and Gajewski TF:
Melanoma-intrinsic β-catenin signalling prevents anti-tumour
immunity. Nature. 523:231–235. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:pp. 402–408. 2001,
View Article : Google Scholar
|
|
18
|
Santegoets SJ, Turksma AW, Powell DJ Jr,
Hooijberg E and de Gruijl TD: IL-21 in cancer immunotherapy: At the
right place at the right time = Oncoimmunology. 2:pp. e245222013,
PubMed/NCBI
|
|
19
|
Croce M, Rigo V and Ferrini S: IL-21: A
pleiotropic cytokine with potential applications in oncology. J
Immunol Res. 2015.696578:2015.
|
|
20
|
Moroz A, Eppolito C, Li Q, Tao J, Clegg CH
and Shrikant PA: IL-21 enhances and sustains CD8+ T cell
responses to achieve durable tumor immunity: Comparative evaluation
of IL-2, IL-15, and IL-21. J Immunol. 173:900–909. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Spolski R and Leonard WJ: Interleukin-21:
A double-edged sword with therapeutic potential. Nat Rev Drug
Discov. 13:379–395. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shao J, Xu Q, Su S, Meng F, Zou Z, Chen F,
Du J, Qian X and Liu B: Engineered cells for costimulatory
enhancement combined with IL-21 enhance the generation of
PD-1-disrupted CTLs for adoptive immunotherapy. Cell Immunol.
320:38–45. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Qu QX, Xie F, Huang Q and Zhang XG:
Membranous and cytoplasmic expression of PD-L1 in ovarian cancer
cells. Cell Physiol Biochem. 43:1893–1906. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tang Y, Fang W, Zhang Y, Hong S, Kang S,
Yan Y, Chen N, Zhan J, He X, Qin T, et al: The association between
PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced
non-small cell lung cancer patients treated with EGFR-TKIs.
Oncotarget. 6:14209–14219. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mu CY, Huang JA, Chen Y, Chen C and Zhang
XG: High expression of PD-L1 in lung cancer may contribute to poor
prognosis and tumor cells immune escape through suppressing tumor
infiltrating dendritic cells maturation. Med Oncol. 28:682–688.
2011. View Article : Google Scholar
|
|
26
|
Pang L, Han S, Jiao Y, Jiang S, He X and
Li P: Bu Fei Decoction attenuates the tumor associated macrophage
stimulated proliferation, migration, invasion and immunosuppression
of non-small cell lung cancer, partially via IL-10 and PD-L1
regulation. Int J Oncol. 51:25–38. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li T, Ren J, Ma J, Wu J, Zhang R, Yuan H
and Han X: LINC00702/miR-4652-3p/ZEB1 axis promotes the progression
of malignant meningioma through activating Wnt/β-catenin pathway.
Biomed Pharmacother. 113:1087182019. View Article : Google Scholar
|
|
28
|
Jing JC, Feng Z, Chen ZH, Ji BN, Hong J,
Tang N, Yu JL and Wang SY: KDM4B promotes gastric cancer metastasis
by regulating miR-125b-mediated activation of Wnt signaling. J Cell
Biochem. 2018.
|
|
29
|
Yang Y, Liu L, Cai J, Wu J, Guan H, Zhu X,
Yuan J and Li M: DEPDC1B enhances migration and invasion of
non-small cell lung cancer cells via activating Wnt/β-catenin
signaling. Biochem Biophys Res Commun. 450:899–905. 2014.
View Article : Google Scholar : PubMed/NCBI
|
